BREVICON 28-DAY
LOE ApproachingNDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREVICON 28-DAY is an oral contraceptive tablet approved in 1976 by AbbVie, containing a combination of hormonal agents for prevention of pregnancy. The product uses a 28-day dosing cycle designed for ease of patient compliance. It is a small-molecule hormonal therapy indicated for contraception in women of reproductive age.
LOE Approaching
Late-stage lifecycle with high competitive pressure (30) signals a consolidating franchise focused on retention and operational efficiency rather than growth headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BREVICON 28-DAY as a pharmaceutical professional means focusing on defending market share and operational efficiency in a mature, crowded market rather than driving growth or innovation. Roles are primarily commercial and compliance-oriented, with limited exposure to cutting-edge development or clinical strategy.
Brand ManagerField Sales Representative
Worked on BREVICON 28-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.